Teva Pharmaceutical Industries Ltd. is terminating its American Depositary Share (ADS) program and will conduct a mandatory exchange of all outstanding ADSs for its ordinary shares. This action follows the company's previously disclosed intent to list its ordinary shares directly on the New York Stock Exchange (NYSE).
Key Details
- Effective Date: The termination and mandatory exchange will occur at the open of business (New York time) on September 14, 2026.
- Exchange Terms: Each outstanding ADS will be cancelled and automatically exchanged for one NYSE-listed ordinary share on a one-for-one basis.
- Agreement: The process is facilitated by an amendment, executed on August 31, 2026, to the company's deposit agreement with Citibank, N.A.